Brainsway (BWAY)
NASDAQ:BWAY
Want to see BWAY full AI Analyst Report?
BWAY Stock Chart & Stats
$15.81
-$0.11(-1.13%)
At close: 4:00 PM EST
$15.81
-$0.11(-1.13%)
Day’s Range― - ―
52-Week Range$5.04 - $17.35
Previous CloseN/A
Volume9.67K
Average Volume (3M)138.00K
Market Cap
$581.70M
Enterprise Value$612.13M
Total Cash (Recent Filing)$59.77M
Total Debt (Recent Filing)$6.71M
Price to Earnings (P/E)63.1
Beta1.49
Next Earnings
Aug 12, 2026EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.37
Shares Outstanding40,087,600
10 Day Avg. Volume140,784
30 Day Avg. Volume137,995
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.48
Price to Sales (P/S)3.47
P/FCF Ratio11.06
Enterprise Value/Market Cap1.05
Enterprise Value/Revenue10.89
Enterprise Value/Gross Profit14.42
Enterprise Value/Ebitda48.70
Forecast
1Y Price Target
$17.00Price Target Upside7.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.19
Revenue Forecast (FY)$67.17M
Bulls Say, Bears Say
Bulls Say
High Gross Margins & ProfitabilitySustained mid‑70s gross margins and a swing to positive net income provide durable operating leverage. High product margins support reinvestment in sales, clinical studies and service infrastructure, enabling profitable scale as installed base and recurring revenue grow.
Conservative Balance Sheet / Cash RunwayLow leverage and a large cash position give the company flexibility to fund commercial expansion, clinical programs, and strategic minority investments without immediate financing risk. This financial cushion reduces solvency risk and supports multi‑year growth plans.
Recurring Revenue Base & Growing RPOA growing installed base plus multiyear leases/RPO convert hardware placements into predictable recurring revenue. This ARR‑like profile increases revenue visibility, improves unit economics over time and supports operating leverage as utilization and consumables sales expand.
Bears Say
Reimbursement & Regulatory DependencyLong‑term commercial traction depends on broader payer coverage and regulatory approvals for new indications and protocols. Delays or restrictive policies would slow clinic adoption, constrain utilization growth, and postpone realization of projected recurring revenue and margin gains.
Cash Conversion VolatilityWhile cash generation is positive, uneven historical operating cash and a recent FCF decline signal working‑capital or reinvestment sensitivity. Persistent volatility could limit reinvestment capacity or force financing choices if growth accelerates and cash conversion normalizes lower.
Rising Opex And Investment Execution RiskHigher S&M, R&D and strategic funding increase near‑term capital deployment and execution burden. If clinical readouts, partner commercialization or payer uptake lag, these investments could pressure margins and cash flow, requiring disciplined prioritization to protect returns.
Brainsway News
BWAY FAQ
What was Brainsway’s price range in the past 12 months?
Brainsway lowest stock price was $5.04 and its highest was $17.35 in the past 12 months.
What is Brainsway’s market cap?
Brainsway’s market cap is $581.70M.
When is Brainsway’s upcoming earnings report date?
Brainsway’s upcoming earnings report date is Aug 12, 2026 which is in 70 days.
How were Brainsway’s earnings last quarter?
Brainsway released its earnings results on May 13, 2026. The company reported $0.03 earnings per share for the quarter, the consensus estimate of $0.03 by $0.
Is Brainsway overvalued?
According to Wall Street analysts Brainsway’s price is currently Undervalued.
Does Brainsway pay dividends?
Brainsway does not currently pay dividends.
What is Brainsway’s EPS estimate?
Brainsway’s EPS estimate is 0.05.
How many shares outstanding does Brainsway have?
Brainsway has 40,087,600 shares outstanding.
What happened to Brainsway’s price movement after its last earnings report?
Brainsway reported an EPS of $0.03 in its last earnings report, expectations of $0.03. Following the earnings report the stock price went down -2.569%.
Which hedge fund is a major shareholder of Brainsway?
Currently, no hedge funds are holding shares in BWAY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Brainsway Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.00 (7.53% Upside)
$17.00 (7.53% Upside)
Blogger Sentiment
Bullish
BWAY Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 36.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 7.6%
Last 30 Days ▼ 7.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
202.74%
12-Months-Change
Fundamentals
Return on Equity
12.28%
Trailing 12-Months
Asset Growth
16.77%
Trailing 12-Months
Company Description
Brainsway
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
BWAY Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights strong operational execution and solid financial momentum: 35% revenue growth, 11th consecutive profitable quarter, substantial increases in net income and adjusted EBITDA, meaningful unit shipments (117 systems, +44% YoY), and expanding remaining performance obligations ($75M, +25% YoY). Management also presented attractive clinical advances (SWIFT results: ~70% reduction in clinic visits; 88% response, 78% remission) and clear strategic initiatives (Neurolief investment, minority stakes in provider networks, positive VA pricing). Key risks noted include higher operating expenses due to growth investments, reliance on payer adoption and FDA timing for new indications and protocols, and ongoing investments that increase near-term capital deployment. Overall, positives materially outweigh the challenges, with strong guidance for continued growth but some execution and reimbursement risks to monitor.View all BWAY earnings summariesBWAY Stock 12 Month Forecast
Average Price Target
$17.00
▲(7.53% Upside)
Technical Analysis
Sanuwave Health
―
Tactile Systems Technology
―
Viemed Healthcare
―
TriSalus Life Sciences
―
NeuroPace
―
Ownership Overview
0.03% Insiders
0.93% Mutual Funds
22.00% Other Institutional Investors
76.60% Public Companies and
Individual Investors